Boston Family Office LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 59.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,773 shares of the life sciences company's stock after selling 4,060 shares during the quarter. Boston Family Office LLC's holdings in Illumina were worth $371,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Bleakley Financial Group LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $751,000. Zacks Investment Management bought a new stake in shares of Illumina during the 3rd quarter valued at $2,924,000. Van ECK Associates Corp grew its position in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock worth $20,347,000 after buying an additional 22,718 shares during the period. Strategic Financial Concepts LLC bought a new position in shares of Illumina in the 4th quarter worth about $1,464,000. Finally, Allworth Financial LP increased its stake in shares of Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock worth $1,001,000 after acquiring an additional 6,263 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Stock Performance
Shares of NASDAQ:ILMN traded down $2.26 during midday trading on Friday, hitting $74.16. The company had a trading volume of 3,912,056 shares, compared to its average volume of 2,222,582. The company has a market cap of $11.75 billion, a price-to-earnings ratio of -9.66, a PEG ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a fifty day moving average of $96.82 and a two-hundred day moving average of $125.06. Illumina, Inc. has a 12-month low of $70.64 and a 12-month high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Analyst Ratings Changes
ILMN has been the topic of a number of recent research reports. Stephens restated an "overweight" rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Piper Sandler upped their price target on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Robert W. Baird lowered their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Guggenheim cut their target price on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and lowered their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $140.90.
View Our Latest Research Report on ILMN
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
